U.S. regulators are delaying their decision on Moderna's COVID-19 vaccine for 12- to 17-year-olds while they study the rare risk of heart inflammation, the company said Sunday.
The U.S. Food and Drug Administration told the company Friday evening that its review could last until January, Moderna said.
The company also said it will delay filing a request for emergency-use authorization of a lower dose of the vaccine for 6- to 11-year-olds. Heart inflammation is an exceedingly rare risk of both the Pfizer and Moderna vaccines, and it more commonly seen in young men or boys. It's difficult for clinical trials to detect such a rare problem. And public health officials have repeatedly stressed that COVID-19 itself can cause heart inflammation at higher rates than the rare cases caused by the vaccine.Moderna said more than 1.
Moderna also has been testing two shots, one month apart, for children 6 to 11, at half the dose given to adults.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Canada to donate 10 million doses of Moderna vaccine to COVAXCanada will donate 10 million doses of Moderna's COVID-19 vaccine to the COVAX vaccine sharing facility and donate $15 million to help make mRNA vaccines in Africa.
Read more »
Canada will donate 10 million doses of Moderna’s COVID-19 vaccine to COVAXIncluding financial supports, Justin Trudeau says Canada will help deliver at least 200 million shots of COVID-19 vaccines to developing countries
Read more »